# Study of ABO2102 in KRAS-Mutated Solid Tumors

> **NCT07455617** · PHASE1 · RECRUITING · sponsor: **Suzhou Abogen Biosciences Co., Ltd.** · enrollment: 101 (estimated)

## Conditions studied

- Advanced / Metastatic Solid Tumor

## Interventions

- **DRUG:** ABO2102 Injection
- **DRUG:** Sintilimab injection

## Key facts

- **NCT ID:** NCT07455617
- **Lead sponsor:** Suzhou Abogen Biosciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-24
- **Primary completion:** 2029-06
- **Final completion:** 2030-02
- **Target enrollment:** 101 (ESTIMATED)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07455617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07455617, "Study of ABO2102 in KRAS-Mutated Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07455617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*